Acalabrutinib

Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK). It can dose-dependently inhibit B cell receptor signaling in primary chronic lymphocytic leukemia cells. In kinase-inhibition assays, acalabrutinib was more selective than ibrutinib (Cay-16274) for inhibiting BTK and did not inhibit EGFR, Itk, or Txk signaling.Formal Name: 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-benzamide. CAS Number: 1420477-60-6. Synonyms: ACP-196. Molecular Formula: C26H23N7O2. Formula Weight: 465.5. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 25 mg/ml, DMSO: 25 mg/ml, DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml, Ethanol: 15 mg/ml. lambdamax: 229, 283, 336 nm. SMILES: O=C(NC1=CC=CC=N1)C(C=C2)=CC=C2C3=C(C(N)=NC=C4)N4C([C@@H]5CCCN5C(C#CC)=O)=N3. InChi Code: InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1. InChi Key: WDENQIQQYWYTPO-IBGZPJMESA-N.